ClinicalTrials.gg
CompletedNCT04363554POVAUpdated Apr 30, 2020

The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease

An interventional study of Fluid intake and Thirsting in Polycystic Kidney, Autosomal Dominant and Chronic Kidney Diseases, sponsored by Regional Hospital Holstebro. Completed at 1 site in Denmark. Per ClinicalTrials.gov, last updated 2020-04-30.

Sponsored by Regional Hospital Holstebro · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Sep 2017, registered Apr 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Sex
All
01

Study summary

The ability to concentrate and dilute urine is primarily regulated via vasopressin (AVP) dependent Aquaporin-2 water channels (AQP2 channels) in the kidney's collecting duct. Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disorder, characterized by the formation of cyst in the kidneys, causing gradual renal function-loss. Previous studies indicate that ADPKD patients have decreased urine concentration, higher plasma osmolality, and plasma AVP levels compared to healthy controls. Previous studies also indicate that ADPKD patients' dysregulated AVP is an important factor for the pathogenesis and progression of the disease. It is unclear whether ADPKD patients' ability to concentrate and dilute urine are different from those of other cause of chronic renal disease to the same degree. It is also unclear, what mechanisms cause the decreased ability to concentrate and dilute urine in chronic renal disease patients. The purpose of this trial is to investigate the difference in renal function during concentration and dilution test in a case-control, randomized, cross-examination study with ADKPD patients or other cause of chronic renal disease compared to healthy volunteers.

Read the detailed description

The aim is to measure the difference in renal function, including kidney tubular function, blood pressure and vasoactive hormones in patients with Autosomal dominant polycystic kidney disease (ADPKD) or other chronic renal disease compared to healthy volunteers, during concentration and dilution test.

02

Conditions studied

  • Polycystic Kidney, Autosomal Dominant
  • Chronic Kidney Diseases

Keywords

  • CYSTS
  • KIDNEYS
03

In context

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

This study's enrollment of 51 is close to the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.

Browse Polycystic Kidney, Autosomal Dominant studies →

Lead sponsor

Regional Hospital Holstebro is the lead sponsor of 52 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ADPKD patients: -age >18 years, diagnosis with ADPKD, , for fertile women
  • Patients with chronic kidney disease: age >18 years, diagnosis with chronic kidney disease other then ADPKD, informed consent, contraception for fertile women
  • Healthy volunteers: age >18 years, healthy, informed consent, contraception for fertile women

Exclusion criteria

Exclusion Criteria:

  • ADPKD patients: Renal transplantation, operation in the kidney, Diabetes mellitus, neoplastic conditions, pregnancy, breastfeeding, unwillingness to participate, intolerance towards urine dilution or urine concentration test, alcohol or medical abuse, BP >170/110 despite regulation, unacceptable side effects to background medication (antihypertensive medicine) during the trial.
  • Patients with chronic kidney disease: Renal transplantation, operation in the kidney, Diabetes mellitus, medullary cystic kidney disease, lithium nephropathy, neoplastic conditions, pregnancy, nursing, unwillingness to participate, intolerance towards urine dilution or urine concentration test, alcohol or medical abuse, BP >170/110 despite regulation, unacceptable side effects to background medication (antihypertensive medicine) during the trial.
  • Healthy volunteers: Arterial hypertension, significant clinical signs of heart, lungs, liver, kidneys, endocrine, brain or neoplastic disorders, alcohol or drug abuse, medical treatment, smoking, pregnancy or breastfeeding, smoking, abnormal findings in blood, urine tests or , blood donation within the last month before the examination date in the first trial sequence, intolerance to or unacceptable side effects of urine concentration and urine dilution test
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Other
    Urine dilution test

    Urine dilution test

    Other: Fluid intake

  • Other
    Urine concentration test

    Urine concentration test

    Other: Thirsting

Interventions

  • OtherFluid intake

    The participants will intake fluid

  • OtherThirsting

    The participants will thirst

06

What researchers measure

Primary outcomes

  1. free water clearance CH20 u-osm

    free water clearance (CH2O)

    Time frame: 5 hours

  2. u-osm

    urine osmolality

    Time frame: 4 hours

Secondary outcomes

  1. free water clearance

    free water clearance (CH2O)

    Time frame: 5 hours

07

Study locations

1 site
  • Department of Medical Research, Regional Hospital Holstebro
    Holstebro, 7500, Denmark
08

References and documents

Publications

  • Malmberg MH, Mose FH, Pedersen EB, Bech JN. Urine concentration ability is reduced to the same degree in adult dominant polycystic kidney disease compared with other chronic kidney diseases in the same CKD-stage and lower THAN in healthy control subjects - a CASE control study. BMC Nephrol. 2020 Aug 31;21(1):379. doi: 10.1186/s12882-020-02043-w. PubMed 32867720 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Apr 2020, 30 months.

Of 22 interventional studies with no phase under Polycystic Kidney, Autosomal Dominant, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 54. This study's 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2020
First posted
Apr 27, 2020
StartActual
Sep 25, 2017
Primary completionActual
Apr 20, 2020
CompletionActual
Apr 20, 2020
Last update
Apr 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04363554
Lead sponsor
Regional Hospital Holstebro
Responsible party
Jesper Norgaard Bech (Head of University Clinic in Nephrology and Hypertension, Regional Hospital Holstebro) — Principal investigator
First posted
Apr 27, 2020
Start date
Sep 25, 2017
Primary completion
Apr 20, 2020
Completion
Apr 20, 2020
Last update
Apr 30, 2020

Study contacts

My Malmberg, MD
principal investigator · Departments of medical research and medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion